Gilead Sciences (United States)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United States), United States, covering academic research published from 2000 to 2023. Read More.
Open Access Percentage
59%
Total
Publications
4.9K
Total Open
Publications
2.9K
Total
Citations
212K
Open Access
Percentage
59%
Total
Publications
4.9K
Total Open
Publications
2.9K
Total
Citations
212K
Breakdown
Publisher Open
22%
Both
26%
Other Platform Open
11%
Closed
41%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 29%
678
Hybrid 30%
708
No Guarantees 41%
966
Other Platform Open
Domain 88%
1.6K
Institution 25%
450
Other Internet 9%
154
Public 8%
139
Preprint 6%
101
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 1.6K |
Europe PMC | Domain | 966 |
Semantic Scholar | Public | 110 |
DOI | Other Internet | 80 |
University of California - eScholarship University of California | Institution | 57 |
University College London - UCL Discovery | Institution | 54 |
bioRxiv | Preprint | 52 |
California Digital Library - eScholarship | Other Internet | 50 |
University of North Carolina at Chapel Hill - Carolina Digital Repository | Institution | 45 |
Figshare | Public | 37 |